UGP2 and hepatocellular carcinoma: For example, in hepatocellular carcinoma, integrative analysis of genomic, transcriptomic, proteomic, and metabolomic data across cell lines with varying metastatic potential identified dysregulated metabolic pathways, including consistently elevated UGP2, representing a metabolic dependency that could be targeted to reduce malignancy [193].